Regeneron Pharmaceuticals, Inc.(REGN) Q3
EPS: 20.07 USD; Forecast 16.42 USD
Revenue: 5.12B USD; Forecast 4.56B USD
Reporting period: 2026 Q3 (period ended 2026-09-30)
Release date: 2026-10-30